Sarepta Therapeutics (SRPT) said Wednesday that the UK's Medicines & Healthcare products Regulatory Agency has allowed dosing to continue uninterrupted in the phase 3 study of its Elevidys gene therapy treatment.
The study is evaluating the treatment in non-ambulatory and older ambulatory individuals with Duchenne muscular dystrophy, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.